DE602005026545D1 - Modifizierte genomische rna des menschlichen hepatitis-c-virus mit autonomer replikationskompetenz - Google Patents

Modifizierte genomische rna des menschlichen hepatitis-c-virus mit autonomer replikationskompetenz

Info

Publication number
DE602005026545D1
DE602005026545D1 DE602005026545T DE602005026545T DE602005026545D1 DE 602005026545 D1 DE602005026545 D1 DE 602005026545D1 DE 602005026545 T DE602005026545 T DE 602005026545T DE 602005026545 T DE602005026545 T DE 602005026545T DE 602005026545 D1 DE602005026545 D1 DE 602005026545D1
Authority
DE
Germany
Prior art keywords
coding sequence
protein coding
genomic rna
virus genomic
hepatitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005026545T
Other languages
English (en)
Inventor
Takaji Wakita
Takanobu Kato
Tomoko Date
Michiko Miyamoto
Ralf Bartenschlager
Jun-Ichi Tanabe
Saburo Sone
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tokyo Metropolitan Organization for Medical Research
Toray Industries Inc
Original Assignee
Tokyo Metropolitan Organization for Medical Research
Toray Industries Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tokyo Metropolitan Organization for Medical Research, Toray Industries Inc filed Critical Tokyo Metropolitan Organization for Medical Research
Publication of DE602005026545D1 publication Critical patent/DE602005026545D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24241—Use of virus, viral particle or viral elements as a vector
    • C12N2770/24243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Pathology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
DE602005026545T 2004-08-24 2005-08-24 Modifizierte genomische rna des menschlichen hepatitis-c-virus mit autonomer replikationskompetenz Active DE602005026545D1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2004243975 2004-08-24
JP2004290801 2004-10-01
JP2005069527 2005-03-11
JP2005069725 2005-03-11
PCT/JP2005/015833 WO2006022422A1 (ja) 2004-08-24 2005-08-24 自律複製能を有する改変されたヒトｃ型肝炎ウイルスゲノムrna

Publications (1)

Publication Number Publication Date
DE602005026545D1 true DE602005026545D1 (de) 2011-04-07

Family

ID=35967617

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005026545T Active DE602005026545D1 (de) 2004-08-24 2005-08-24 Modifizierte genomische rna des menschlichen hepatitis-c-virus mit autonomer replikationskompetenz

Country Status (13)

Country Link
US (2) US8454973B2 (de)
EP (1) EP1801209B1 (de)
JP (1) JP4931591B2 (de)
KR (1) KR101262773B1 (de)
CN (1) CN101048502B (de)
AT (1) ATE499442T1 (de)
AU (1) AU2005275713B2 (de)
CA (1) CA2578021C (de)
DE (1) DE602005026545D1 (de)
HK (1) HK1112481A1 (de)
PL (1) PL1801209T3 (de)
PT (1) PT1801209E (de)
WO (1) WO2006022422A1 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5086082B2 (ja) * 2004-10-01 2012-11-28 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル Ｃ型肝炎ウイルス複製系
DK1863941T3 (da) 2005-03-04 2013-07-22 Univ Rockefeller Infektiøst, kimæriskt hepatitis-c-virus, fremgangsmåder til fremstilling deraf og fremgangsmåder til anvendelse deraf
US8364417B2 (en) * 2007-02-15 2013-01-29 454 Life Sciences Corporation System and method to correct out of phase errors in DNA sequencing data by use of a recursive algorithm
WO2007098049A2 (en) * 2006-02-16 2007-08-30 454 Life Sciences Corporation System and method for correcting primer extension errors in nucleic acid sequence data
JP2008161080A (ja) * 2006-12-27 2008-07-17 Japan Health Science Foundation Ｃ型肝炎ウイルス阻害剤を検出するためのアッセイ方法
US8454974B2 (en) 2007-04-13 2013-06-04 Hvidovre Hospital Adaptive mutations allow establishment of JFH1-based cell culture systems for hepatitis C virus genotype 4A
US8945584B2 (en) 2007-04-13 2015-02-03 Hvidovre Hospital Cell culture system of a hepatitis C genotype 3a and 2a chimera
AU2008246622B2 (en) * 2007-04-27 2013-09-26 Advanced Life Science Institute, Inc. HCV gene
WO2008141651A1 (en) 2007-05-18 2008-11-27 Hvidovre Hospital Efficient cell culture system for hepatitis c virus genotype 5a
CN101835896A (zh) * 2007-07-13 2010-09-15 日本国立感染症研究所 表位标记的丙型肝炎病毒颗粒的制备和应用
CA2694397A1 (en) * 2007-07-25 2009-01-29 Japan As Represented By Director-General Of National Institute Of Infect Ious Diseases Antibody having inhibitory activity on infection with hepatitis c virus (hcv) and use thereof
WO2009080052A1 (en) 2007-12-20 2009-07-02 Hvidovre Hospital Efficient cell culture system for hepatitis c virus genotype 6a
WO2009080053A1 (en) * 2007-12-20 2009-07-02 Hvidovre Hospital Efficient cell culture system for hepatitis c virus genotype 1a and 1b
CN102016026B (zh) * 2008-04-25 2014-07-02 东丽株式会社 含有来自丙型肝炎病毒的嵌合基因的核酸
US8506969B2 (en) 2008-08-15 2013-08-13 Hvidovre Hospital Efficient cell culture system for hepatitis C virus genotype 7a
WO2010017818A1 (en) 2008-08-15 2010-02-18 Hvidovre Hospital Efficient cell culture system for hepatitis c virus genotype 2b
WO2010038789A1 (ja) 2008-09-30 2010-04-08 東レ株式会社 Ｃ型肝炎ウイルスのエンベロープタンパク質２に結合する抗体及びそれを用いたｃ型肝炎ウイルスの遺伝子型の同定方法
EP2344647A1 (de) 2008-10-03 2011-07-20 Hvidovre Hospital Ns5a-protein mit reporter-tag exprimierendes hepatitis-c-virus
JP5692738B2 (ja) * 2009-07-28 2015-04-01 国立大学法人 鹿児島大学 ウイルスの濃縮方法および磁性体組成物
JPWO2011040535A1 (ja) 2009-09-30 2013-02-28 東レ株式会社 Ｃ型肝炎ウイルスワクチン組成物
WO2011052735A1 (ja) 2009-10-30 2011-05-05 東レ株式会社 C型肝炎ウイルス（hcv）に対して感染阻害活性を有する抗体及びその用途
EP3290529B1 (de) 2010-06-11 2019-05-22 Life Technologies Corporation Alternative nukleotidflüsse in verfahren zur sequenzierung durch synthese
US8981073B2 (en) * 2010-10-08 2015-03-17 Advanced Life Science Institute, Inc. Hepatitis C virus gene
US8666678B2 (en) 2010-10-27 2014-03-04 Life Technologies Corporation Predictive model for use in sequencing-by-synthesis
US10273540B2 (en) 2010-10-27 2019-04-30 Life Technologies Corporation Methods and apparatuses for estimating parameters in a predictive model for use in sequencing-by-synthesis
WO2012118555A1 (en) 2010-12-29 2012-09-07 Life Technologies Corporation Time-warped background signal for sequencing-by-synthesis operations
WO2012092455A2 (en) 2010-12-30 2012-07-05 Life Technologies Corporation Models for analyzing data from sequencing-by-synthesis operations
US10241075B2 (en) 2010-12-30 2019-03-26 Life Technologies Corporation Methods, systems, and computer readable media for nucleic acid sequencing
US20130060482A1 (en) 2010-12-30 2013-03-07 Life Technologies Corporation Methods, systems, and computer readable media for making base calls in nucleic acid sequencing
JPWO2012133735A1 (ja) 2011-03-31 2014-07-28 国立感染症研究所長 遺伝子型１ｂのＣ型肝炎ウイルスゲノム由来の核酸を含む核酸構築物、及び該核酸構築物が導入されたＣ型肝炎ウイルスゲノム複製細胞、並びに感染性Ｃ型肝炎ウイルス粒子の製造方法
CN105861645B (zh) 2011-04-08 2020-02-21 生命科技股份有限公司 用于合成测序中的相保护试剂流排序
JP5927185B2 (ja) 2011-05-31 2016-06-01 国立感染症研究所長 Ｃ型肝炎ウイルスｊ６ｃｆ株ゲノム由来の変異体レプリコン
EP2752485A4 (de) 2011-08-31 2015-06-24 Japan As Represented By The Director General Of Nat Inst Of Infectious Diseases Nukleinsäurekonstrukt mit einer aus einem genom des genotyps 3a-hcv gewonnenen nukleinsäure
US10704164B2 (en) 2011-08-31 2020-07-07 Life Technologies Corporation Methods, systems, computer readable media, and kits for sample identification
WO2013106639A1 (en) * 2012-01-13 2013-07-18 Gilead Pharmasset Llc Crysral structure of hcv polymerase complexes and methods of use
US9646132B2 (en) 2012-05-11 2017-05-09 Life Technologies Corporation Models for analyzing data from sequencing-by-synthesis operations
US10329608B2 (en) 2012-10-10 2019-06-25 Life Technologies Corporation Methods, systems, and computer readable media for repeat sequencing
US20140296080A1 (en) 2013-03-14 2014-10-02 Life Technologies Corporation Methods, Systems, and Computer Readable Media for Evaluating Variant Likelihood
US9926597B2 (en) 2013-07-26 2018-03-27 Life Technologies Corporation Control nucleic acid sequences for use in sequencing-by-synthesis and methods for designing the same
US10410739B2 (en) 2013-10-04 2019-09-10 Life Technologies Corporation Methods and systems for modeling phasing effects in sequencing using termination chemistry
US10676787B2 (en) 2014-10-13 2020-06-09 Life Technologies Corporation Methods, systems, and computer-readable media for accelerated base calling
EP4220645A3 (de) 2015-05-14 2023-11-08 Life Technologies Corporation Barcodesequenzen sowie zugehörige systeme und verfahren
US10619205B2 (en) 2016-05-06 2020-04-14 Life Technologies Corporation Combinatorial barcode sequences, and related systems and methods

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69739268D1 (de) 1996-11-08 2009-04-02 Us Gov Health & Human Serv Herstellung und reinigung von hepatitis c virus-ähnlichen partikeln
AU5322800A (en) * 1999-06-04 2000-12-28 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Cloned genone of infectious hepatitis c virus of genotype 2a and uses thereof
US7329408B2 (en) 1999-12-01 2008-02-12 Novartis Vaccines And Diagnostics, Inc. Eliciting HCV-specific antibodies
IL137522A (en) 2000-07-26 2007-06-17 Drk Blutspendediendst Baden Wu HCV human monoclonal antibody E2 glycoprotein antibody
JP4880116B2 (ja) * 2000-12-01 2012-02-22 財団法人 東京都医学総合研究所 劇症ｃ型肝炎ウイルス株の遺伝子
AU2003230790A1 (en) 2002-04-03 2003-10-20 Smithkline Beecham Corporation Hepatitis c virus sub-genomic replicons
CN1833024B (zh) * 2003-05-26 2011-08-31 东丽株式会社 含有衍生自基因型2a丙肝病毒(HCV)基因组的核酸的核酸构建体和具有转移入其中的这样的核酸构建体的细胞
JP5086082B2 (ja) * 2004-10-01 2012-11-28 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル Ｃ型肝炎ウイルス複製系
DK1863941T3 (da) * 2005-03-04 2013-07-22 Univ Rockefeller Infektiøst, kimæriskt hepatitis-c-virus, fremgangsmåder til fremstilling deraf og fremgangsmåder til anvendelse deraf
CN102016026B (zh) * 2008-04-25 2014-07-02 东丽株式会社 含有来自丙型肝炎病毒的嵌合基因的核酸

Also Published As

Publication number Publication date
JPWO2006022422A1 (ja) 2008-05-08
WO2006022422A1 (ja) 2006-03-02
AU2005275713B2 (en) 2010-08-05
CN101048502B (zh) 2012-03-21
PL1801209T3 (pl) 2011-07-29
EP1801209A1 (de) 2007-06-27
US9175269B2 (en) 2015-11-03
ATE499442T1 (de) 2011-03-15
EP1801209A4 (de) 2007-12-05
EP1801209B1 (de) 2011-02-23
US8454973B2 (en) 2013-06-04
CA2578021A1 (en) 2006-03-02
JP4931591B2 (ja) 2012-05-16
US20130115592A1 (en) 2013-05-09
US20090176200A1 (en) 2009-07-09
KR20070045333A (ko) 2007-05-02
CA2578021C (en) 2014-11-18
KR101262773B1 (ko) 2013-05-10
HK1112481A1 (en) 2008-09-05
CN101048502A (zh) 2007-10-03
PT1801209E (pt) 2011-05-26
AU2005275713A1 (en) 2006-03-02

Similar Documents

Publication Publication Date Title
DE602005026545D1 (de) Modifizierte genomische rna des menschlichen hepatitis-c-virus mit autonomer replikationskompetenz
Pfaender et al. Natural reservoirs for homologs of hepatitis C virus
Epstein et al. Identification of GBV-D, a novel GB-like flavivirus from old world frugivorous bats (Pteropus giganteus) in Bangladesh
Fan et al. The intrinsic disorder status of the human hepatitis C virus proteome
WO2009014216A1 (ja) Ｃ型肝炎ウイルス（hcv）に対して感染阻害活性を有する抗体およびその用途
WO2006096459A3 (en) Infectious, chimeric hepatitis c virus, methods of producing the same and methods of use thereof
JP2008516610A5 (de)
Imhof et al. Development of an intergenotypic hepatitis C virus (HCV) cell culture method to assess antiviral susceptibilities and resistance development of HCV NS3 protease genes from HCV genotypes 1 to 6
DK1629091T3 (da) Præparat indeholdende polyproteinet NS3/NS4 og polypeptidet NS5B af HCV, ekspressionsvektorer omfattende tilsvarende nukleinsyresekvenser og terapeutisk anvendelse deraf
Li et al. Recovery of a chemically synthesized Japanese encephalitis virus reveals two critical adaptive mutations in NS2B and NS4A
EP1930416A4 (de) Neues rekombinantes partikel mit ähnlichkeit zum menschlichen hepatitis-c-virus und verfahren zur herstellung davon
Naderi et al. Hepatitis C virus and vaccine development
ATE555800T1 (de) Zusammensetzung mit dem polyprotein ns3/ns4 und dem polypeptid ns5b von hcv, expressionsvektoren mit den entsprechenden nukleinsäuresequenzen und ihre therapeutische verwendung
Tajima et al. Restoration of replication-defective dengue type 1 virus bearing mutations in the N-terminal cytoplasmic portion of NS4A by additional mutations in NS4B
Londono-Renteria et al. A brief review of West Nile virus biology
Khasnatinov et al. Tick-borne encephalitis virus structural proteins are the primary viral determinants of non-viraemic transmission between ticks whereas non-structural proteins affect cytotoxicity
Manickam et al. Modeling HCV disease in animals: virology, immunology and pathogenesis of HCV and GBV-B infections
US9382517B2 (en) HCV full-length infectious cell culture systems and applications thereof
Lattwein et al. Pestivirus virion morphogenesis in the absence of uncleaved nonstructural protein 2-3
Varshney et al. A review on an update of NS5B polymerase hepatitis C virus inhibitors
Bittar et al. Genetic diversity of NS5A protein from hepatitis C virus genotype 3a and its relationship to therapy response
Sarwar et al. NS4A protein as a marker of HCV history suggests that different HCV genotypes originally evolved from genotype 1b
WO2005032329A3 (en) Methods and compositions for identifying anti-hcv agents
Suzuki et al. Positively selected amino acid sites in the entire coding region of hepatitis C virus subtype 1b
Chopra Characteristics of the hepatitis C virus

Legal Events

Date Code Title Description
R097 No opposition filed against granted patent, or epo opposition proceedings concluded without decision

Ref document number: 1801209

Country of ref document: EP

R082 Change of representative

Ref document number: 1801209

Country of ref document: EP

Representative=s name: PRUEFER & PARTNER GBR, 81479 MUENCHEN, DE